European Pharmaceutical Review

FEBRUARY 8, 2023

GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.

Marketing 98

Marketing Sales Physicians Patients 98

Evolve Your Success

OCTOBER 31, 2023

He provides a fascinating glimpse into what it takes to excel in the field of medical device sales, emphasizing the importance of authenticity and passion. Blake has a unique case because he was a cardiac, cath lab, critical care, and surgery nurse who got into medical sales. People come from sales, clinical, and engineers.

Engineering 52

Engineering Sales Medical sales Medical 52

Pharmaceutical Technology

MAY 19, 2023

AbbVie anticipates Rinvoq sales to exceed $7.5bn in 2025 and for the peak revenues from both drugs to exceed Humira’s peak sales by 2027.

Food and Drug Administration 105

Food and Drug Administration FDA Sales Food 105

pharmaphorum

JULY 18, 2022

The market research group recently predicted Vydura and atogepant will achieve sales of $35 million and $57 million, respectively, by 2030 in the five major European markets of France, Germany, Italy, Spain, and the UK. GlobalData has said it expects Qulipta to get approval for chronic migraine prevention in 2023, helping it to sales of $1.2

Sales 52

Sales Marketing Patients FDA 52

pharmaphorum

SEPTEMBER 22, 2022

The company said this morning that US sales growth is its main priority, and that it will be led in the near-term by “high-value” new drugs Kisqali (ribociclib), iptacopan, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), remibrutinib, and Scemblix (asciminib). billion by 2024.

Management 52

Management Sales Patients Marketing 52

pharmaphorum

OCTOBER 17, 2022

9,187,405, granted in 2015, which comes to an end in 2027. If they do so, Novartis has predicted it will lose $300 million in sales over the remainder of this year. Sales in the first half of this year fell 19% to $1.16 Gilenya made revenues of $2.8

Competition 52

Competition Marketing Sales Pharma 52

Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Merck has also permitted the sale of generic versions of Janumet XR to the market in July 2026 or before. The suit involved two Merck patents. The first is for the dihydrogen phosphate salt of sitagliptin.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69

pharmaphorum

OCTOBER 6, 2022

Lilly already has approval for the dual GLP-1/GIP agonist under the Mounjaro brand name as a diabetes therapy and is tipped to make rapid inroads in that market, with EvaluatePharma predicting sales could break the $1 billion barrier in 2024, and $3 billion two years later. billion in 2025 sales.

Sales 52

Sales Marketing FDA Leads 52

pharmaphorum

JANUARY 9, 2023

Albireo secured approval in the US and Europe for the ileal bile acid transport inhibitor (IBATi) drug in 2021 for the treatment of pruritus (itching) in patients with rare disorder progressive familial intrahepatic cholestasis (PFIC), and has said sales should reach $24 million this year. billion deal.

Transportation 52

Transportation Sales Leads FDA 52

Pharmaceutical Technology

DECEMBER 16, 2022

This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales. GlobalData’s report also covers a third pipeline candidate, quinagolide, a dopamine receptor antagonist being developed by Ferring Pharmaceuticals.

Marketing 59

Marketing Side effects Sales Safety 59

pharmaphorum

SEPTEMBER 21, 2022

The pharma group has been fighting an attempt by Chinese drugmaker HEC Pharma to bring a generic version of fingolimod to market in the US, and in 2020 won a permanent injunction on any such launch until the ‘405 patent expires in December 2027 – protecting billions of dollars in revenues.

Competition 52

Competition Pharma Sales Marketing 52

pharmaphorum

JULY 26, 2022

It had expected the drug would not face biosimilar competition in Europe until at least 2027. The company is in the process of considering a possible sale of Sandoz, although it has stressed it may opt to retain the business or spin it out.

Competition 52

Competition Side effects Marketing Sales 52

pharmaphorum

NOVEMBER 2, 2022

Abiomed makes the bulk of its $1 billion-plus annual sales from its Impella range of heart pumps, which are billed as the smallest such devices available in the world, and have enjoyed double-digit growth for several quarters as well as margins upwards of around 22%. Impella heart pump. Joaquin Duato.

Sales 52

Sales Medical Marketing Manufacturing 52

pharmaphorum

SEPTEMBER 23, 2022

Novartis said at a management update yesterday that Leqvio is one of eight in-market brands with multi-billion dollar peak sales potential, although it is still in its rollout phase and has a long way to go. billion in sales by 2027, ahead of Repatha at $2.2 billion in sales by 2027, ahead of Repatha at $2.2

Sales 59

Sales Education Pharma Patients 59

pharmaphorum

JULY 18, 2022

Tysabri made worldwide sales of just under $2.1 It had expected the drug would not face biosimilar competition in Europe until at least 2027. billion last year, split roughly half and half between the US and the rest of the world, and is Biogen’s biggest seller. Europe accounted for an estimated $850 million of the total.

Competition 52

Competition Marketing Sales Medicine 52

pharmaphorum

OCTOBER 1, 2022

Sales in the first half of this year fell 19% to $1.16 The latest judgments relate to an attempt by Chinese drugmaker HEC Pharma to bring a generic version of fingolimod to market in the US, and Novartis defense of the 9,187, 405 patent which expires in December 2027. Gilenya made revenues of $2.8

Competition 52

Competition Pharma Marketing Sales 52

European Pharmaceutical Review

JANUARY 10, 2023

Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide.

Food and Drug Administration 98

Food and Drug Administration FDA Food Medicine 98

Clarivate

AUGUST 27, 2024

and ramped up sales of PFA systems in Europe. Based on brisk uptake in the latter half of the first quarter, it appeared that PFA would account for at least 30% of the ablation market and $1 billion in sales by the end of 2024. Since the FDA’s approval of the first pulsed field ablation (PFA) system in the U.S. s Farapulse.

Marketing 52

Marketing Competition FDA Electronics 52

PM360

SEPTEMBER 21, 2023

Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

pharmaphorum

NOVEMBER 18, 2022

Prior to the FDA rejection, GlobalData was predicting global peak sales of $691 million for teplizumab in 2027, and some analysts were even more optimistic with forecasts of around $2 billion at peak.

FDA 52

FDA Patients Manufacturing Sales 52

pharmaphorum

JANUARY 27, 2023

Earlier this month, Clarivate released a list of new drugs to watch in 2023 and beyond, with new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers”, according to Clarivate.

Pharma 52

Pharma Manufacturing Medicine Biopharma 52

Legacy MEDSearch

SEPTEMBER 20, 2022

The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027. It is approved for sale in the United States, European Union, Japan, and Canada. About OpSens Inc. www.OpSens.com or www.OpSensmedical.com ). OpSens focuses mainly in interventional cardiology.

FDA 52

FDA Food and Drug Administration Recruitment Physicians 52

Contrarian Sales Techniques

MAY 1, 2023

billion in 2019, and experts predict it will skyrocket to almost $60 billion by 2027. A Booming Market with a Broader Scope The self-improvement industry is a massive and ever-growing market, providing an array of products and services aimed at helping individuals improve their personal and professional lives.

Ethics 52

Ethics Marketing Government Management 52

Medico Reach

FEBRUARY 8, 2023

Pharma companies can utilize big data to predict the sale of a particular medicine owing to various demographic factors. billion by 2027. Global personalized medicine market forecast for the year 2027: Source The leading pharma firms are designing revolutionary, custom-made treatment methods.

Pharma 52

Pharma Medicine Marketing Prospecting 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

JANUARY 10, 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate.

FDA 52

FDA Marketing Pharma Sales 52

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.”

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

World of DTC Marketing

JUNE 4, 2021

If the trend continues at the current rate, millennial treatment costs are still projected to be close to $4,500 annually, roughly 33 percent higher than those of Generation X at a comparable age, by 2027. According to Euromonitor’s most recent data, Americans remain the world leaders when it comes to per capita sales of soft drinks.

Food 207

Food Insurance Leads Medical 207

Pharmaceutical Technology

JANUARY 10, 2023

billion in sales in 2019, increasing to $136.2 billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Mounjaro is forecast to compete for significant market share with semaglutide and also Lilly’s Trulicity (dulaglutide), reaching peak sales of $10.2

Marketing 52

Marketing Physicians Leads Sales 52

PM360

JULY 13, 2023

MarketsandMarkets, “Polyols Market by Type, Application, End-use Industry, and Region – Global Forecast to 2027,” December 2022. Additional contributions to this article were provided by Vincent Attonito, Technical Sales Manager, Deloitte Consulting LLP and Kate Pacheco, Senior Consultant, Deloitte Consulting LLP. References: 1.

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

Clarivate

JULY 16, 2019

By 2027, 75% percent of today’s S&P 500 companies will be replaced by new companies which are providing the best customer experience to their customers. 18x increase in average sales cycle time. Trillion is the annual cost of customer churn due to poor experiences. REVENUE Benefits of CX. RETENTION Benefits of CX.

Competition 40

Competition Sales Leads Marketing 40

Legacy MEDSearch

MAY 23, 2022

BN by 2027. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs. This system has helped propel the arthroscopic market to an expected US $16.3

Food and Drug Administration 52

Food and Drug Administration Medicine Recruitment Physicians 52

Legacy MEDSearch

JULY 24, 2023

Trial results are expected in 2027. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

Medical 52

Medical Recruitment FDA Patients 52

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Top companies and drugs by sales in 2021. 2022;21(4):251–.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

PM360

SEPTEMBER 21, 2023

aging population, a rise in the net per capita spending on specialty drugs, an increased life expectancy (apart from the impact of COVID), and the increasing prevalence of chronic diseases are expected to boost the specialty pharmaceuticals market to $352 billion by 2027. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

Prescription 52

Prescription Medical Patients Distribution 52

PM360

JUNE 29, 2022

By 2025, sales of consumer health products are expected to reach $368bn, according to Euromonitor, encompassing everything from sleep aids to vitamins to sports nutrition products. markets by 2025 and 1,000 by 2027—and more than half of those practices are expected to be in medically underserved communities.

Retail 97

Retail Marketing Healthcare Healthcare 97

Infuse Medical

NOVEMBER 16, 2021

billion industry by 2027. Additionally, have sales representatives accessible in case their expertise is required. Displaying these effectively build attendee relationships in a branded environment in the absence of in-person events. Virtual Exhibition Booths and the Future. Proactively Engage With Your Audience.

Networking 52

Networking Media Leads Management 52